Compagnie Lombard Odier S Cm A Intellia Therapeutics, Inc. Transaction History

Compagnie Lombard Odier S Cm A

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$34.58 - $46.03 $51,870 - $69,045	1,500 Added 100.0%	3,000 $122,000
Q3 2022 Nov 09, 2022	SELL	$53.92 - $71.7 $24,264 - $32,265	-450 Reduced 23.08%	1,500 $84,000
Q1 2022 Apr 27, 2022	BUY	$58.27 - $118.99 $26,221 - $53,545	450 Added 30.0%	1,950 $142,000
Q3 2021 Oct 28, 2021	SELL	$132.37 - $176.78 $198,555 - $265,170	-1,500 Reduced 50.0%	1,500 $201,000
Q2 2021 Jul 15, 2021	SELL	$60.88 - $161.91 $17.2 Million - $45.7 Million	-282,520 Reduced 98.95%	3,000 $486,000
Q1 2021 Apr 23, 2021	BUY	$46.59 - $83.68 $13 Million - $23.4 Million	279,520 Added 4658.67%	285,520 $22.9 Million
Q4 2020 Feb 09, 2021	SELL	$18.83 - $63.53 $75,320 - $254,120	-4,000 Reduced 40.0%	6,000 $326,000
Q4 2019 Feb 13, 2020	BUY	$10.43 - $17.67 $20,860 - $35,340	2,000 Added 25.0%	10,000 $147,000
Q1 2019 May 13, 2019	BUY	$12.79 - $17.62 $12,790 - $17,620	1,000 Added 14.29%	8,000 $137,000
Q3 2017 Nov 14, 2017	BUY	$15.16 - $25.75 $37,900 - $64,375	2,500 Added 55.56%	7,000 $174,000
Q2 2017 Aug 14, 2017	BUY	N/A	4,500	4,500 $72,000

334

95.4M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $613M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.